ORM-12741

Generic Name
ORM-12741
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H23NO2
CAS Number
610782-82-6
Unique Ingredient Identifier
C5D3YG7ZR8
Background

ORM-12741 has been used in trials studying the basic science and treatment of Alzheimer's Disease.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: ORM-12741
Drug: Placebo
First Posted Date
2018-02-20
Last Posted Date
2019-01-10
Lead Sponsor
University of Cape Town
Target Recruit Count
68
Registration Number
NCT03440021
Locations
๐Ÿ‡ฟ๐Ÿ‡ฆ

UCT Dept. Psychiatry & Mental Health / CUBIC, Cape Town, Western Cape, South Africa

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
Drug: ORM-12741
First Posted Date
2015-06-15
Last Posted Date
2018-02-15
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
308
Registration Number
NCT02471196
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

Clinical Research Services Turku - CRST Oy, Turku, Finland

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

First Posted Date
2011-03-29
Last Posted Date
2021-04-28
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
100
Registration Number
NCT01324518
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

Clinical Research Services Turku (CRST), Turku, Finland

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo for ORM-12741
Drug: ORM-12741
First Posted Date
2010-02-12
Last Posted Date
2010-08-16
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
49
Registration Number
NCT01068028
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Forenap Pharma, Rouffach, France

Early Phase I Microdosing Study of ORM-14540 and ORM-12741

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ORM-14540
Drug: ORM-12741
First Posted Date
2009-01-28
Last Posted Date
2009-10-08
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
6
Registration Number
NCT00831077
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

CRST, Turku, Finland

A PET Study With ORM-12741

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ORM-12741
First Posted Date
2009-01-27
Last Posted Date
2009-11-25
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
26
Registration Number
NCT00829907
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

Turku PET centre, Turku, Finland

Pharmacokinetic Study of ORM-12741 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: ORM-12741
First Posted Date
2009-01-08
Last Posted Date
2009-10-08
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
12
Registration Number
NCT00818740
Locations
๐Ÿ‡ซ๐Ÿ‡ฎ

CRST, Turku, Finland

Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741

Phase 1
Completed
Conditions
Healthy Male Volunteers
Interventions
Drug: ORM-12741
First Posted Date
2009-01-06
Last Posted Date
2009-03-16
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
6
Registration Number
NCT00817544
Locations
๐Ÿ‡ณ๐Ÿ‡ฑ

PRA International, AE Zuitlaren, Netherlands

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ORM-12741
First Posted Date
2008-11-18
Last Posted Date
2009-09-24
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
51
Registration Number
NCT00792493
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Forenap Pharma, Rouffach, France

Safety and Tolerability Study With Single Ascending Doses of ORM-12741

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ORM-12741
First Posted Date
2008-06-09
Last Posted Date
2010-02-11
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
120
Registration Number
NCT00693316
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Forenap Pharma, Rouffach, France

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy